Trikafta 100-50-75 MG/75MG PKT 14S
Ended Awarded Last action
- Contract number
- SPE2DR26FQWK9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $57,995
Award facts
- Contract value 100% obligated
- $57,994.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $57,994.83 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Trikafta 100-50-75 mg tablets in packets of 14 units. The award, issued on January 13, 2026, with an ultimate completion date of January 14, 2026, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy designed to supply pharmaceutical products to military healthcare facilities worldwide.
DMS Pharmaceutical Group serves as a critical regional prime vendor contractor under the PPV-G GEN V initiative, which was awarded with a $499.999 billion ceiling value through December 31, 2036. The company's portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables that support Department of Defense healthcare operations. This delivery order for Trikafta, a cystic fibrosis treatment medication, reflects the vendor's established performance supplying diverse and specialized pharmaceutical requirements across the federal military medical system, with no subcontractor relationships identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FQWK9?
SPE2DR26FQWK9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FQWK9 worth?
The government has obligated $57,995 on SPE2DR26FQWK9.
Is contract SPE2DR26FQWK9 an order under another contract?
Yes. SPE2DR26FQWK9 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWK9 competed?
The extent of competition for SPE2DR26FQWK9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award